GIP-Targeted Drug Development for Diabetes
Drugs targeting the GIPR provide an exciting therapeutic option for insulin resistance and diabetes. Ace
Therapeutics is committed to applying our expertise in diabetes to provide targeted diabetes drug
development services for GIP. Our capabilities in animal models of diabetes and preclinical pharmacological assays
allow us to offer new strategies for the treatment of obesity-associated diabetes, from early screening to
preclinical evaluation.
Gastric Inhibitory Polypeptide (GIP) as A Promising Therapeutic Target for Diabetes
Gastric inhibitory peptide is an incretin hormone secreted by small intestinal K cells and its main functions
include:
- Promotes insulin secretion: GIP stimulates insulin secretion by binding to the GIP receptor (GIPR) on pancreatic
β-cells, thereby lowering blood glucose levels.
- Inhibits glucagon secretion: GIP inhibits the release of glucagon, further balancing blood sugar.
- Delayed gastric emptying: GIP regulates postprandial glucose spikes through delayed gastric emptying.
- Suppresses appetite: GIP also affects appetite through the central nervous system, reducing food intake.
Currently, GIPR agonists demonstrate amelioration of insulin resistance and reduced body weight gain in response to
high fat feeding. These advances suggest that GIPR is an exciting target for obesity diabetes.
Fig. 1 GIP mediated mechanism for insulin
secretion from β-cells. (Dhankhar, S. et al., 2023)
GIP-Targeted Antidiabetic Drug Development Services at Ace Therapeutics
As a specialist preclinical contract research organization, Ace Therapeutics offers antidiabetic drug development
services targeting the GIP (Glucose-dependent Insulinotropic Polypeptide) pathway, spanning from early-stage
screening to preclinical testing. We are committed to providing customized solutions to accelerate our clients'
antidiabetic drug development process.
Research on GIP-related mechanisms and signaling pathway analysis
- GIP receptor Functional Studies: We assess the role of GIP receptors in insulin secretion,
glucagon regulation and energy metabolism through cellular and animal models.
- Signaling pathway analysis: We use molecular biology techniques to analyze GIP-related signaling
pathways (e.g. cAMP/PKA, PI3K/Akt) and reveal their mechanisms of action.
Customized diabetes model development
- Type 2 diabetes models: We provide high-fat
diet-induced, db/db mice, ZDF rats, and other models for evaluating the efficacy of GIP-targeted
drugs.
- β-cell function models: We develop β-cell specific injury models to study the effects of GIP on
β-cell function.
In
vivo and in
vitro pharmacodynamic analyses
- In vitro experiments: We use in vitro models such as pancreatic islet cells
and adipocytes to assess the effects of GIP drugs on glucose uptake, insulin secretion, and cell
function.
- In vivo experiments: We assess drug effects in improving glycaemic control and insulin
sensitivity through oral glucose tolerance test (OGTT) and insulin tolerance test (IPITT).
Pharmacokinetic &
safety analysis
- Pharmacokinetic (PK) studies: We evaluate the absorption, distribution, metabolism and excretion
(ADME) properties of GIP drugs in animals.
- Toxicological studies: We conduct acute toxicity, sub-acute toxicity and long-term toxicity
tests to ensure the safety of the drug.
Biomarker development
services
- Biomarker screening: Screening of biomarkers related to the mechanism of action of GIP through
proteomics, metabolomics and other technologies.
- Preclinical validation: We validate the reliability and sensitivity of biomarkers in animal
models to support clinical trials.
Synergistic development of multi-target mechanisms
- Synergistic studies of GIP with other targets: We can help our clients to study the synergistic
effects of GIP and GLP-1 receptor agonists to develop multi-targeted antidiabetic drugs.
- Combination Evaluation: We evaluate the efficacy of GIP drugs in combination with existing
antidiabetic drugs (e.g., metformin, SGLT2 inhibitors).
Advantages of Our GIP-Targeted Antidiabetic Drug Development Services
- Comprehensive technical tools: We have advanced cell and animal experimental platforms, which are capable of
conducting GIP receptor function studies, signaling pathway analyses, pharmacodynamic evaluations, and so on.
- Flexible collaboration model: We provide one-stop services from target validation to preclinical research, or
provide specific support according to clients' needs.
- Animal model development: We provide a variety of customized diabetes animal models that mimic human disease
characteristics.
Ace Therapeutics' GIP-targeted antidiabetic drug development services are based on the core
strengths of professionalism, customization and comprehensiveness. We are committed to providing our clients with
efficient and reliable solutions to accelerate their programs in drug discovery and development. If you have any
related needs, please feel free to contact us.
References
- Dhankhar, S.; et al. Novel targets for potential therapeutic use in Diabetes mellitus. Diabetology
& Metabolic Syndrome. 2023, 15(1): 17.
- Irwin, N.; et al. Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of
countering insulin resistance in the treatment of obesity-diabetes. Peptides. 2020, 125: 170203.
- Joo, E.; et al. Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue
reduces insulin resistance and hepatic steatosis in high-fat diet-fed mice. Diabetes. 2017, 66(4):
868-879.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
